ÂÜÀòÂÒÂ×

John Ford's work experience includes a range of leadership roles in the biopharmaceutical industry. John is currently the Executive Chairman at ARMGO Pharma, Inc., where they oversee the development of drug therapies for cardiac, musculoskeletal, and neurological disorders. John also serves as the Chairman at Complement Therapeutics.

Previously, John served as the CEO of Enterprise Therapeutics, focusing on the development of muco-regulatory therapies for respiratory diseases. In 2016, Roche/Genentech acquired the TMEM16A portfolio from Enterprise Therapeutics. John was also the Co-Owner & Investor Director at Metrion Biosciences, a contract research organization specializing in ion channel screening services.

Prior to that, John was the Co-Founder & CEO of Ario Pharma, a company that developed TRPV1 inhibitors for Type 2 Diabetes. John also co-founded Xention Discovery, where they served as the CSO and worked on atrial fibrillation treatments. Xention's IKur/Kv1.5 project reached Phase 2a and was partnered with Servier.

John has held positions in other notable companies in the industry, including AKARNA THERAPEUTICS, LTD, where they served as the General Manager of UK Operations before the company was acquired by Allergan, and Dezima Pharma B.V., where they were the COO until the company was acquired by Amgen.

At the start of their career, John worked as a Team Leader at BioFocus Discovery Ltd, where they were responsible for cell-based drug discovery campaigns and assay development.

Overall, John Ford has extensive experience in leadership and drug development in the biopharmaceutical industry, with a particular focus on developing therapies for various diseases and conditions.

John Ford attended Robert Smyth Grammar School from 1988 to 1992. Following their time at the grammar school, they moved on to the University of Leeds, where they studied Biochemistry & Pharmacology. John completed their bachelor's degree and achieved first-class honors in 1998. Additionally, John earned their Ph.D. from the University of Leeds in the same field of study.